Adding quizartinib to venetoclax drove AML remissions in an early-phase trial
In a 74-patient phase 1/2 study, venetoclax-based therapy plus the FLT3 inhibitor quizartinib produced remissions in about half of older adults unfit for chemo, and more in the FLT3-mutated subgroup.
Adding the targeted drug quizartinib to a venetoclax-based regimen produced remissions in roughly half of older adults with acute myeloid leukaemia who were too frail for intensive chemotherapy, in an early-phase trial published in the Journal of Hematology & Oncology [s1]. The benefit was most pronounced in the small subgroup whose leukaemia carries the genetic change quizartinib is designed to hit. But this was a phase 1/2 trial with no comparison against the venetoclax backbone alone, so it establishes activity and safety — not added benefit.
The problem the trial addresses
Many people diagnosed with acute myeloid leukaemia (AML) are older and cannot tolerate intensive chemotherapy. For them, a lower-intensity backbone — the oral drug venetoclax combined with either the hypomethylating agent azacitidine or low-dose cytarabine — has become a standard option [s1]. Quizartinib is an oral, selective inhibitor of FLT3, a signalling protein that is abnormally activated in a subset of AML; it is already approved in combination with intensive chemotherapy for newly diagnosed AML carrying a FLT3 "internal tandem duplication" (FLT3-ITD) [s1]. The VEN-A-QUI trial asked whether quizartinib could be layered onto the lower-intensity venetoclax backbone for patients who cannot have intensive treatment.
What the trial did
This was a phase 1/2, multicentre, prospective, open-label trial in patients aged 60 or older with newly diagnosed AML — either FLT3-ITD-positive or -negative — who were ineligible for intensive chemotherapy [s1]. Two parallel regimens were tested: venetoclax plus azacitidine plus quizartinib (VEN-AZA-Quiz), and venetoclax plus low-dose cytarabine plus quizartinib (VEN-LDAC-Quiz) [s1]. A phase 1 dose-escalation set the quizartinib dose, after which phase 2 patients were randomised 1:1 between the two regimens [s1]. The primary endpoints were the recommended phase 2 dose of quizartinib in phase 1 and the composite complete remission (CRc) rate in phase 2 [s1]. The trial is registered as NCT04687761 [s2].
Fourteen patients were treated in phase 1 and 60 in phase 2 [s1]. The recommended phase 2 dose of quizartinib was 60 mg/day in the azacitidine arm and 40 mg/day in the low-dose cytarabine arm [s1].
What it found
In phase 2, a composite complete remission by cycle 4 was reached in 18 of 31 patients (58.1%) on VEN-AZA-Quiz and 15 of 29 (51.7%) on VEN-LDAC-Quiz, with no significant difference between the two arms (p = 0.80) [s1]. Median overall survival was 16.9 months with VEN-AZA-Quiz and 8.9 months with VEN-LDAC-Quiz (p = 0.81), with three-year survival rates of 22.6% and 27.6% [s1].
Two signals stood out. Among patients whose leukaemia was FLT3-ITD-positive — quizartinib's intended target — the composite remission rate was 10 of 13 (76.9%) and median overall survival reached 29.3 months [s1]. And the type of leukaemia mattered more than the regimen: median overall survival was 32 months for patients with newly arising (de novo) AML versus 7.5 months for those whose AML followed an earlier blood disorder or treatment (secondary AML), a highly significant gap (p less than 0.001) [s1]. The most common adverse events were infections and blood-count toxicity [s1].
How to read it
The central caution is structural. This was a small, early-phase trial — 74 patients treated in all — and it did not include an arm receiving the venetoclax backbone without quizartinib [s1]. Without that comparison, the trial cannot say how much quizartinib adds; the remission rates are in the range already seen with venetoclax-based therapy, so the question of incremental benefit is left open.
The near-identical p-values between the two arms (0.80 for remission, 0.81 for survival) should not be read as proof that the regimens are equivalent — the trial was not sized to detect a difference between them, and with these numbers it could not have. The strongest-looking result, in FLT3-ITD-positive patients, rests on just 13 people; it is biologically coherent and encouraging, but it is hypothesis-generating, not confirmatory. The poor outcomes in secondary AML are a reminder that disease biology drove survival here as much as the drugs did.
What to watch
The result that would change practice is a randomised comparison of the venetoclax backbone with and without quizartinib, focused on FLT3-mutated older patients, with longer follow-up to see whether the early survival signal holds. Until that exists, VEN-A-QUI shows the three-drug combination is deliverable and active in a frail population — a foundation for a larger trial, not a reason to adopt it as standard [s1].
This article describes early clinical-trial results and is not medical advice. Decisions about leukaemia treatment are for patients and their treating haematologists.
Sources
- Upfront venetoclax plus quizartinib with low-dose cytarabine or azacitidine in older unfit patients with acute myeloid leukemia: the phase I/II VEN-A-QUI trial — Journal of Hematology & Oncology , November 15, 2026
- Safety and Tolerability of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML (NCT04687761) — ClinicalTrials.gov
More on
Adding a third AML drug missed overall, but hinted at a benefit in one mutation group
In 120 older adults with acute myeloid leukaemia, adding midostaurin to two-drug therapy did not raise remission rates overall (72% vs 68%), but a small FLT3-mutated subgroup lived longer.
A gentler drug pair beat intensive chemo on one measure in fit leukaemia patients
In the 172-patient PARADIGM trial, azacitidine plus venetoclax more than doubled median event-free survival versus induction chemotherapy — but it was a phase 2 study not powered for overall survival.
ENHANCE: magrolimab added toxicity but no benefit in higher-risk MDS
Gilead's phase 3 trial in 539 patients was terminated after the CD47 antibody failed to improve remission or survival and caused more fatal adverse events than azacitidine alone.
Pirtobrutinib added to venetoclax-rituximab slows relapse in treated CLL
In the phase 3 BRUIN CLL-322 trial, adding pirtobrutinib to a fixed course of venetoclax and rituximab raised 24-month progression-free survival to 87% from 72% in previously treated disease.